LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (Nasdaq: ALNY) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Alnylam shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On October 5, 2016 Alnylam announced that it would discontinue development of revusiran (an investigational RNA interference therapeutic for the treatment of hereditary ATTR amyloidosis with cardiomyopathy) due to patient safety concerns. The Company stated that reports indicated patients taking revusiran in midstage trials had new or worsening complications of the disease. When this information became public, shares of Alnylam dropped in value.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.